ARTICLES PUBLISHED IN SCIENTIFIC JOURNALS
Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE; Fosamax Actonel Comparison Trial Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin. 2004 Dec;20(12):2031-41.
Rackoff, P, Sebba A: Optimizing Administration of Bisphosphonates in Women with Post Menopausal Osteoporosis Treat Endocrinol. 2005;4(4):245-51.
Furst DE, Martin S, Sebba AI, and the Hi-dose HCQ study group, et al: Hi-dose hydroxychloroquine in rheumatoid arthritis – results of a six (6) week, pharmacokinetic dose-loading, double-blind controlled study with an 18 week extension. Arth Rheum 40(9) 1997. Link is here.
Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, Dietz F, Ettlinger R, Golden HE, Lindsley H, McLaughlin GE, Moreland LW, Roberts WN, Rooney TW, Rothschild B, Sack M, Sebba AI, Weisman M, Welch KE, Yocum D, Furst DE. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002 Jun;46(6):1460-9. Link is here.
Bingham CO 3rd, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS,Fitzgerald BJ, O’brien K, Tershakovec AM Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford). 2006 Aug 27. Link is here.
Bonnick S, Saag KG, Kiel DP, McClung M, Hochberg M, Burnett SM, Sebba A, Kagan R, Chen E, Thompson DE, de Papp AE. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006 Jul;91(7):2631-7. Link is here.
Bonnick S, Saag KG, Kiel DP, McClung M, Hochberg M, Burnett SA, Sebba A, Kagan R, Chen E, Thompson DE, de Papp AE Comparison of weekly treatment of postmenopausal osteoporosis with alendronate
Sebba AI. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.Clin Ther. 2008 Mar;30(3):443-52.
Sebba AI . Efficacy and Safety of Etoricoxib in the treatment of Osteoarthritis .Expert Rev.Clin. Pharm 1(3) 345 355 (2008)
Sebba AI, Broy S, Kohles JD, Weissman P.Rapid Suppression of Bone Resorption Marker Levels With Ibandronate Therapy in a Bisphosphonate-Naïve Population.J Clin Densitom. 2008 May 2.
Sebba A.Tocilizumab: the first interleukin-6-receptor inhibitor.Am J Health Syst Pharm.
2008 Aug 1;65(15):1413-8
Sebba A. Osteoporosis: how long should we treat? Bone. 2009 Mar;44(3):423-7.
Epub 2008 Nov 12.
Sebba AI, Emkey RD, Kohles JD, Sambrook PN. Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Curr Opin Endocrinol Diabetes Obes. 2008 Dec;15(6):502-7.
Sebba A. Comparing non-vertebral fracture risk reduction with osteoporosis therapies: looking beneath the surface J Bone Miner Res. 2008 Dec 29. [Epub ahead of print]
Watts NB, Miller PD, Kohlmeier LA, Sebba A, Chen P, Wong M, Krohn K. Vertebral Fracture Risk is Reduced in Women Who Lose Femoral Neck Bone Mineral Density with Teriparatide Treatment. J Bone Miner Res. 2008 Dec 29.
Burnett-Bowie SA, Saag K, Sebba A, de Papp AE, Chen E, Rosenberg E, Greenspan SL.
Prediction of Changes in Bone Mineral Density in Postmenopausal Women Treated With Once-Weekly Bisphosphonates. J Clin Endocrinol Metab. 2009 Jan 13. Link is here.
Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis. 2009 Mar 17. Link is here.
Rieke Alten, Juan Gomez-Reino, Patrick Durez, Andre Beaulieu, Anthony Sebba, Gerhard Krammer, Ralph Preiss, Udayasankar Arulmani, Albert Widmer, Xavier Gitton, Herbert Kellner. Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumabin rheumatoid arthritis: results of a 12-week, phase II, dose-finding study. BMC Musculoskeletal Disorders 2011, 12:153. Link is here.
Silverman S, Miller P, Sebba A, Weitz M, Wan X, Alam J, Masica D, Taylor KA, Ruff VA, Krohn K. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results. Osteoporos Int. 2013 Feb 12. [Epub ahead of print] PubMed PMID: 23404615. Link is here.
Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gómez-Reino J, Sebba A, Pilson R, Williams S, van Vollenhoven R. Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. J Rheumatol. 2013 Mar 1. [Epub ahead of print] PubMed PMID: 23457383.
Emery P, Sebba A, Huizinga TW.Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis.Ann Rheum Dis. 2013 Aug 10. doi: 10.1136/annrheumdis-2013-203485. Link is here.
PRESENTATIONS & ABSTRACTS AT NATIONAL AND INTERNATIONAL SCIENTIFIC MEETINGS
Marcus RE, Sebba AI: Remission and Toxicity Using Single and Double Combination DMARD Therapy in 196 Patients with Rheumatoid Arthritis. Arth Rheum 1991 Suppl.
Marcus RE, Sebba AI: Comparison of Efficacy and Toxicity of Single and Combination DMARD Therapy in 263 Patients with Rheumatoid Arthritis. Arth Rheum 37(6) 1994 Suppl.
Zizic TM, Alatis LJ, Sebba AI, et al: Clinical and Cost Effectiveness of Pulsed Electrical Stimulation Treated Knee OA in Total Knee Replacement Candidates Arth Rheum 38(9) 1995
Blackburn WD, Prupos, HM, Silverfield JC, Sebba AI, et al: Tenidap in Rheumatoid Arthritis: A 24-Week Double Blind Comparison with Hydroxychloroquine-Plus-Piroxicam, and Piroxicam Alone. Arth Rheum 38(10) 1995
S. Bonnick1, K. Saag2, S.-A. Burnett3, M. Hochberg4, A. Sebba5, R. Kagan6, E. Rosenberg7, E. Chen7, A.E. de Papp7 Greater Gains in BMD with Once- weekly Alendronate Compared to Once-weekly risedronate: 2-year Results from the FOSAMAX® ACTONEL® Comparison Trial (FACT);. Abstract ISCD 2006
R.Kagan1, A.Sebba2, S.Bonnick3, K.Saag4, M.Hochberg5, D.Thompson6, E. Chen6, A.E. de Papp6, Abstract NAMS 2005 More Patients Gain BMD with Alendronate than Risedronate after 24 Months
Kagan, R., Sebba, A., (2005). Early assessment of response to bisphosphonate therapy with biochemical markers of bone turnover. [Abstract]. Obstetrics & Gynecology 105, 108S. versus risedronate over two years. J Clin Endocrinol Metab. 2006 Jul;91(7):2631-7.
Epub 2006 Apr 24.
Greenspan S, Sebba A, Saag K,Thompson D, Rosenberg E, Chen E, de Papp AE Early Reductions in Bone Turnover Markers Are Associated with 24-Month Bone Mineral Density Response and Non-response in the FOSAMAX ACTONEL Comparison Trial (FACT) Abstract ASBMR 2006
Saag K1,MD, Sebba A2, MD, Bonnick S3,MD, Rosenberg E4, PhD, Chen E4, MD, de Papp AE4, BASELINE CHARACTERISTICS OF NON-RESPONDERS TO BISPHOSPHONATE THERAPY IN THE FOSAMAX ACTONEL COMPARISON TRIAL (FACT) ECCHEO 2006
Anthony Sebba, MD1, Kenneth Saag2, MD, Sydney Bonnick, MD3, Elizabeth Rosenberg, PhD4, Erluo Chen, MD, MPH4, Anne E. de Papp, Identifying Non-Responders to Risedronate or Alendronate in the FOSAMAX® ACTONEL® Comparison Trial (FACT).ECTS 2006
Burnett, SM, Greenspan SL, Sebba A, Rosenberg E, Chen E, de Papp AE Early Reductions in Biochemical Markers of Bone Turnover Are Associated with 24-Month Increases in Bone Mineral Density in the FOSAMAX ACTONEL Comparison Trial (FACT) Abstract 2006 Endocrine Society
Saag K1,MD, Sebba A2, MD, Bonnick S3,MD, Rosenberg E4, PhD, Chen E4, MD, de Papp AE4, Baseline Characteristics of Non-responders to Bisphosphonate Therapy in the FACT Study Abstract ISCD 2006
David M. Reid, MD1, David Hosking, MD2, Kenneth Saag, MD3, Anthony Sebba, MD4, Elizabeth Rosenberg, PhD5, Erluo Chen, MD, MPH5, Nadia Verbruggen, MSc5, Mary Melton, MD5, Anne. de Papp, MD5 MORE PATIENTS GAIN BMD WITH ALENDRONATE THAN RISEDRONATE AFTER 24 MONTHS: RESULTS OF THE US AND INTERNATIONAL FOSAMAX® ACTONEL® COMPARISON TRIALS (FACTS) Abstract IOF 2006
AI Sebba RD Emkey WA Blumenthals,P Sambrook.Relationship between Annual Cumulative Exposure to Ibandronate, BMD increases and clinical fracture reduction. ACR Oct 2007
Sebba AI,Calvo A,Li X et al. Monotherapy improves quality of life compared with methotrexate monotherapy in patients with rheumatoid arthritis: the AMBITION study [poster FRI0174]. 2008 annual European Congress of Rheumatology 2008 June 11-14; Paris
Jones G, Gu JR, Lowenstein M,Sebba A et al. Tocilizumab monotherapy is superior to MTX monotherapy in reducing disease activity in patients with rheumatoid arthritis: the AMBITION study. Poster OP-0131 presented at the Annual European Congress of Rheumatology, 11-14 June 2008,
John D. Carter1, Anthony I. Sebba2, Nancy L. Albritton1, Angie H. Osorio1, Ginger L. Pfeiffer2, Joanne Valeriano1 and Frank B. Vasey1, 1University of South Florida, Tampa, FL, 2Palm Harbor, FL A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis
Marc Hochberg; University of Maryland School of Medicine; USA | Anthony Sebba; Arthritis Associates; USA | Steven Harris; University of California, San Francisco; USA | Brian Calingaert; RTI Health Solutions; USA | William Irish; CTI; USA | Charles Barr; Hoffmann-La Roche Inc.; USA | Bann-Mo Day; Roche; USA | Dennis Black; University of California, San Francisco; USA Relationship Between Change in Bone Mineral Density And Nonvertebral Fracture Risk Reduction In Osteoporosis Trials: Results From an Updated Meta-Analysis
G. Jones, A. Sebba, A. Calvo, G. Tate, A. Beaulieu, E. Vernon, M.C. Genovese. Efficacy of Tocilizumab in patients with rheumatoid arthritis who had never been exposed to or never had failed methotrexate: analysis of up to 3 years of treatment in a long-term extension study. EULAR 2010 Fri 0213
C.O. Bingham, A.I. Sebba , B.R. Rubin , G.E. Ruoff , J. Kremer , S. Bird , S.S. Smugar , B.J. Fitzgerald K. O’Brien , A.M. Tershakovec. Efficacy and safety of etoricoxib 30 mg and celevcoxib 200 mg in the treatment of osteoarthritis in two identically-designed, randomized, placebo-controlled studies.
P. Durez, V. Chindalore, B. Wittmer, M. Cohen, J. Tornero, A. Kivitz, C. Codding, R. DiGiovanni, J. Gomez-Reino, S. Clevinger, F. Blanco, P.P. Tak, K. Yoon, D. Koh, P.L.C. Van Riel, B. Manger, U. Müller-Ladne, H. Schulze-Koops, A. Sebba, J. Kenik, A.M. Wright21, G. Bruin, F. Di Padova, W. AIN 457 anti IL17 antibody shows good safety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate methotrexate therapy in a randomized, double-blind proof-of –concet trial. EULAR 2009 LB 0002
G. Jones,J.J. Gomez-Reino, M.B. Lowenstein, J. Tornero A. Sebba, E. Alecock, E. Guarin, M. Genovese Efficacy of tocilizumab (TCZ) vs methotrexate (MTX) monotherapy in patients with rheumatoid arthritis with no prior MTX or DMARD experience. EULAR 2009 FRI 0252
A.I. Sebba, A. Calvo, X. Li, M. Lowenstein, V. Basijokiene, M. Saavedra-Salinas, T. Reitblat, R. Faraawi8, A. Kivitz9, R. Blackburn10, T. Woodworth10, G. Jones11 Tocilizumab monotherapy improves quality of life compared with methotrexate monotherapy in patients with rheumatoid arthritis: the AMBITION study. EULAR FRI 0174
M. Genovese, A. Sebba, A. Rubbert-Roth, J. Scali, M. Zilberstein, L. Thompson, R.F. van Vollenhoven. Long-term safety of Tocilizumab in rheumatoid arthritis clinical trials.
EULAR 2011 SAT 0270.
Graeme Jones, Anthony Sebba, Denise Lepley,Jenny Devenport, Corrado Bernasconi, Devi Smart, Chiedzo Mpofu and Juan J. Gomez-Reino. Long-Term Efficacy of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Previously Methotrexate Naive or Methotrexate ACR 2012
MC Genovese,1 A Sebba,2 A Rubbert-Roth,3 JJ Scali,4 R Alten,5 JM Kremer,6 L Pitts,7 E Vernon,7 RF van Vollenhoven8. Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis following a Mean Treatment Duration of 3.7 Years EULAR 2013.